Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Bioanalytical Systems	Auxly Cannabis Group	Pieris Pharmaceuticals	Luna Innovations	Eloxx Pharmaceuticals
Symbol	NASDAQ:BASI	OTCMKTS:CBWTF	NASDAQ:PIRS	NASDAQ:LUNA	NASDAQ:ELOX
Price Information
Current Price	$23.14	$0.27	$1.88	$11.67	$1.35
52 Week Range	Buy	Buy	Buy	Buy	Hold
MarketRank™
Overall Score	1.2	1.4	1.4	1.3	1.2
Analysis Score	1.5	3.5	3.5	2.5	3.0
Community Score	2.3	3.0	2.6	2.5	2.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	0.8	0.8	0.0
Earnings & Valuation Score	0.6	0.6	0.0	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Hold
Consensus Price Target	$17.00	$0.40	$9.00	$14.50	$4.00
% Upside from Price Target	-26.53% downside	47.33% upside	378.72% upside	24.25% upside	196.30% upside
Trade Information
Market Cap	$257.57 million	$203.55 million	$119.01 million	$366.42 million	$64.61 million
Beta	1.92	0.61	1.4	1.23	2.57
Average Volume	122,925	1,943,103	540,237	204,361	219,525
Sales & Book Value
Annual Revenue	$60.47 million	$6.29 million	$46.28 million	$70.52 million	N/A
Price / Sales	4.26	32.36	2.57	5.20	N/A
Cashflow	$0.04 per share	N/A	N/A	$0.32 per share	N/A
Price / Cash	558.40	N/A	N/A	36.78	N/A
Book Value	$0.69 per share	$0.31 per share	$0.93 per share	$2.40 per share	$0.91 per share
Price / Book	33.54	0.88	2.02	4.86	N/A
Profitability
Net Income	$-4,680,000.00	$-77,300,000.00	$-25,470,000.00	$5.34 million	$-50,870,000.00
EPS	($0.35)	N/A	($0.56)	$0.17	($1.34)
Trailing P/E Ratio	N/A	N/A	N/A	64.83	N/A
Forward P/E Ratio	578.50	∞	N/A	44.88	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-7.75%	-332.96%	-59.11%	7.21%	N/A
Return on Equity (ROE)	-42.74%	-47.37%	-55.20%	10.72%	-163.87%
Return on Assets (ROA)	-6.38%	-28.34%	-21.21%	8.32%	-89.65%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	2.49%	0.53%	N/A	N/A	0.52%
Current Ratio	0.48%	1.82%	4.50%	4.37%	3.23%
Quick Ratio	0.46%	0.91%	4.50%	3.57%	3.23%
Ownership Information
Institutional Ownership Percentage	10.62%	0.01%	57.46%	42.38%	21.49%
Insider Ownership Percentage	11.46%	N/A	6.59%	11.20%	33.40%
Miscellaneous
Employees	397	431	111	411	25
Shares Outstanding	11.13 million	749.71 million	63.30 million	31.40 million	47.86 million
Next Earnings Date	N/A	6/7/2021 (Estimated)	5/17/2021 (Estimated)	5/17/2021 (Confirmed)	8/5/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	Eloxx Pharmaceuticals Prices Public Offering of 33.3M Shares at $1.35 Each marketwatch.com - May 14 at 12:26 PM
	Why Bionano Genomics, CorMedix and Eloxx Are Moving Friday markets.businessinsider.com - May 14 at 11:12 AM
	Eloxx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock finance.yahoo.com - May 14 at 7:26 AM
	Eloxx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock finance.yahoo.com - May 14 at 12:47 AM
	Eloxx Pharmaceuticals (NASDAQ:ELOX) Issues Quarterly Earnings Results, Misses Expectations By $0.06 EPS americanbankingnews.com - May 10 at 7:38 AM
	Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides ... apnews.com - May 6 at 6:23 PM
	Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update finance.yahoo.com - May 6 at 6:23 PM
	Zacks: Analysts Expect Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Will Post Earnings of -$0.16 Per Share americanbankingnews.com - May 5 at 7:14 PM
	BRIEF-Eloxx Pharmaceuticals Adds Additional Treatment Arm To Ongoing Phase 2 Clinical Studies For Cystic Fibrosis msn.com - April 29 at 8:30 PM
	Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis finance.yahoo.com - April 29 at 5:39 PM
	Eloxx Pharmaceuticals (ELOX) Is in Oversold Territory: What's Next? finance.yahoo.com - April 20 at 10:01 AM
	Eloxx Buys Zikani Therapeutics In An All-Stock Deal; Shares Gain finance.yahoo.com - April 5 at 12:45 PM
	Eloxx nabs early-stage biotech Zikani Therapeutics, replaces CEO, research lead fiercebiotech.com - April 1 at 12:17 PM
	Eloxx Stock is Trading Higher After Zikani Therapeutics Acquisition finance.yahoo.com - April 1 at 12:17 PM
	Eloxx Pharma Acquires Zikani Therapeutics markets.businessinsider.com - April 1 at 8:44 AM
	BRIEF-Eloxx Pharmaceuticals Acquires Zikani Therapeutics msn.com - April 1 at 8:44 AM
	Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results ... apnews.com - March 12 at 1:43 AM
	Eloxx Pharmaceuticals, Inc. (ELOX) Q4 2020 Earnings Call Transcript finance.yahoo.com - March 12 at 1:28 AM
	Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update finance.yahoo.com - March 11 at 6:08 PM
	Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide ... apnews.com - March 5 at 1:00 AM
	Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021 finance.yahoo.com - March 4 at 7:59 PM
	Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)’s 23.22% Gain This Week Just Tells Us Something New marketingsentinel.com - March 1 at 12:21 PM
	Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Cystic Fibrosis finance.yahoo.com - February 9 at 7:23 AM
	Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology in Drug Development finance.yahoo.com - January 26 at 7:31 AM
	Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical ... apnews.com - January 21 at 2:09 AM

Date	Company	Brokerage	Action
3/9/2021	Bioanalytical Systems	Colliers Securities	Reiterated Rating
3/10/2021	Auxly Cannabis Group	Cantor Fitzgerald	Initiated Coverage
9/1/2020	Auxly Cannabis Group	Raymond James	Reiterated Rating
7/16/2020	Auxly Cannabis Group	Desjardins	Initiated Coverage
4/26/2021	Pieris Pharmaceuticals	HC Wainwright	Reiterated Rating
8/9/2020	Pieris Pharmaceuticals	William Blair	Reiterated Rating
3/13/2020	Pieris Pharmaceuticals	Robert W. Baird	Upgrade
5/13/2019	Pieris Pharmaceuticals	Cowen	Reiterated Rating
3/12/2021	Luna Innovations	B. Riley	Boost Price Target
3/6/2020	Luna Innovations	Northland Securities	Downgrade
10/2/2018	Luna Innovations	Dawson James	Initiated Coverage
6/10/2020	Eloxx Pharmaceuticals	Citigroup	Downgrade
5/12/2020	Eloxx Pharmaceuticals	Canaccord Genuity	Reiterated Rating
5/8/2020	Eloxx Pharmaceuticals	Janney Montgomery Scott	Lower Price Target
5/8/2020	Eloxx Pharmaceuticals	Piper Sandler	Lower Price Target
8/8/2019	Eloxx Pharmaceuticals	SunTrust Banks	Lower Price Target

(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources